Lin Liangguang, general manager of Uni Pharma (Photo/Ye Yijun)
Uni Pharma has successfully completed the setting up of its neuromedicine laboratory on May 31, which will provide more than 10 kinds of neoantigen tests with the technology platform of Euroimmun in Germany to assist in clinical research in neuromedicine.
Since 2010, Uni Pharma has been actively stepping into the field of new drug research and development, in addition to the research and development of new ingredients and new drugs, it is also committed to the development of a variety of biomarkers for clinical needs, which are used for tumor detection, polyneuropathy, monitoring of tumor associated syndromes, etc., which are currently services that cannot be provided in domestic clinical practice.
In addition to applying for the establishment license of a medical inspection institution, the laboratory set up by Huayu will also apply for ISO 15189 medical laboratory certification to ensure the reliability of experimental data and quality. General Manager Lin Liangguang said that since September 2015, the book “The Days I Was Crazy: Autobiography of Anti-NMDA Receptor Encephalitis Survivors” written by New York Times reporter Suzanne Kahalan was released on the shelves, which has aroused the rush and interest of many readers.
The book “The Days I Was Crazy” is Suzanne Cahalan’s personal experience and record of her illness, and once again opens a page that neuroscience has not yet explored for mankind. Although science is advancing rapidly and the medical community continues to focus on the research and diagnosis of diseases, there are still many unknown areas in medicine, and there are no very reliable methods for diagnosis or diagnosis of many diseases.
In the case of the book “The Days I Was Crazy”, few people know that tumor diseases can produce neuroscientific manifestations even before the commonly used tumor markers in clinical practice can be warned, so they are called tumor associated syndromes. Huayu hopes to assist in the detection and diagnosis of various incurable neuroscience diseases such as tumor associated syndromes, and develop potential methods to shorten the window period from disease onset to diagnosis.
